ReviewGene therapy2009
AAV for pain: steps towards clinical translation.
Review in Gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Interactions and Trends of Interleukins, PAI-1, CRP, and TNF-α in Inflammatory Responses during the Perioperative Period of Joint Arthroplasty: Implications for Pain Management-A Narrative Review.Journal of personalized medicine · 2024Review
- Long-term reversal of chronic pain behavior in rodents through elevation of spinal agmatine.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Sigma-1 receptor activity in primary sensory neurons is a critical driver of neuropathic pain.Gene therapy · 2022Article
- Intrathecal Drug Delivery: Advances and Applications in the Management of Chronic Pain Patient.Frontiers in pain research (Lausanne, Switzerland) · 2022Review
- Frontiers in Pain Research: A Scope of Its Focus and Content.Frontiers in pain research (Lausanne, Switzerland) · 2020Article
- Cytokines in Pain: Harnessing Endogenous Anti-Inflammatory Signaling for Improved Pain Management.Frontiers in immunology · 2019Review
- Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65.Molecular therapy. Methods & clinical development · 2018Article
- Glial fibrillary acidic protein promoter determines transgene expression in satellite glial cells following intraganglionic adeno-associated virus delivery in adult rats.Journal of neuroscience research · 2018Article
- Experimental Gene Therapy with Serine-Histogranin and Endomorphin 1 for the Treatment of Chronic Neuropathic Pain.Frontiers in molecular neuroscience · 2017Article
- AAV-Mediated Gene Transfer to Dorsal Root Ganglion.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Getting miRNA Therapeutics into the Target Cells for Neurodegenerative Diseases: A Mini-Review.Frontiers in molecular neuroscience · 2016Review
- The therapeutic potential of interleukin-10 in neuroimmune diseases.Neuropharmacology · 2015Review
- Current gene therapy using viral vectors for chronic pain.Molecular pain · 2015Review
- A compact dual promoter adeno-associated viral vector for efficient delivery of two genes to dorsal root ganglion neurons.Gene therapy · 2014Article
- Human pain and genetics: some basics.British journal of pain · 2013Article
- Intraganglionic AAV6 results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats.PloS one · 2013Article
- GCH1, BH4 and pain.Current pharmaceutical biotechnology · 2011Review
- Lentiviral gene transfer into the dorsal root ganglion of adult rats.Molecular pain · 2011Article
- AAV provides an alternative for gene therapy of the peripheral sensory nervous system.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Efficient retrograde transport of adeno-associated virus type 8 to spinal cord and dorsal root ganglion after vector delivery in muscle.Human gene therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Recombinant adeno-associated virus (rAAV) vectors consisting of self-complementary genomes and packaged in certain capsids can target primary sensory neurons efficiently and can control neuropathic pain long term by expressing opioid or non-opioid analgesic genes. This review examines the therapeutic potential of the approach in five sections: Pain control in oncology (including a discussion of cancer centers as translational pain research environment); vector biology; safety considerations and immunological lessons learned from rAAV clinical trials of other disorders; development of intrathecal rAAV therapy in rodent models of pain; and preclinical steps towards clinical translation of rAAV for pain. In the field of analgesic drug development, clinical validation of new approaches identified in rodents is currently a critical limiting step. Small-molecule therapeutics suitable as conventional drugs to probe novel targets in clinical trials are often unavailable. In this context, gene therapy could fill an important gap in the drug development process facilitating first-into-human trials of untested targeted treatments, each instantiated as a therapeutic gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.